Table 1. Association of PP2A phosphorylation/inhibition with molecular and clinical parameters in 230 BC patients.

	No. Cases	No. CPscore 0 (%)		No. CPscore 1 (%)		No. CPscore 2 (%)		p
CPscore	230	168	(73.0)	37	(16.1)	25	(10.9)
T	230	168		37		25		0.552
1	113	83	(49.4)	19	(51.4)	11	(44.0)
2	93	65	(38.7)	16	(43.2)	12	(48.0)
3	22	19	(11.3)	1	(2.7)	2	(8.0)
4	2	1	(0.6)	1	(2.7)	0	(0.0)
N	230	168		37		25		0.077
0	134	104	(61.9)	17	(45.9)	13	(52.0)
1	52	31	(18.5)	14	(37.8)	7	(28.0)
2	26	22	(13.1)	3	(8.1)	1	(4.0)
3	18	11	(6.5)	3	(8.1)	4	(16.0)
Stage	228	167		37		24		0.168
1	84	68	(40.7)	9	(24.3)	7	(29.2)
2	101	66	(39.5)	21	(56.8)	14	(58.3)
3	43	33	(19.8)	7	(18.9)	3	(12.5)
Grade	230	168		37		25		0.017
1	33	29	(17.3)	1	(2.7)	3	(12.0)
2	108	84	(50.0)	14	(37.8)	10	(40.0)
3	89	55	(32.7)	22	(59.5)	12	(48.0)
Morphological type	104	83		15		6		0.754
IDC	97	76	(91.6)	15	(100.0)	6	(100.0)
ILC	6	6	(7.2)	0	(0.0)	0	(0)
Others	1	1	(1.2)	0	(0.0)	0	(0)
ER	230	168		37		25		<0.001
Negative	90	52	(31.0)	18	(48.6)	20	(80.0)
Positive	140	116	(69.0)	19	(51.4)	5	(20.0)
PR	230	168		37		25		<0.001
Negative	107	65	(38.7)	20	(54.1)	22	(88.0)
Positive	123	103	(61.3)	17	(45.9)	3	(12.0)
HER2	230	168		37		25		0.049
Negative	157	121	(72.0)	24	(64.9)	12	(48.0)
Positive	73	47	(28.0)	13	(35.1)	13	(52.0)
Hormonal status	222	161		36		25		0.115
Premenopausal	59	41	(25.5)	14	(38.9)	4	(16.0)
Postmenopausal	163	120	(74.5)	22	(61.1)	21	(84.0)
Relapse	230	168		37		25		<0.001
No	158	126	(75.0)	23	(62.2)	9	(36.0)
Yes	72	42	(25.0)	14	(37.8)	16	(64.0)
Ki-67	230	168		37		25		<0.001
Low	151	123	(73.2)	14	(37.8)	14	(56.0)
High	79	45	(26.8)	23	(62.2)	11	(44.0)
p-ERK	211	152		34		25		<0.001
No	150	134	(88.2)	12	(35.3)	4	(16.0)
Yes	61	18	(11.8)	22	(64.7)	21	(84.0)
p-AKT	220	161		34		25		<0.001
No	147	128	(79.5)	16	(47.1)	3	(12.0)
Yes	73	33	(20.5)	18	(52.9)	22	(88.0)

IDC: invasive ductal carcinoma; ILC: invasive lobular carcinoma; ER: estrogen receptor; PR: progesterone receptor; HR: hormone receptor.